These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19520124)

  • 1. Xenogeneic delivery of therapeutic products using transient immunosuppression.
    Park K
    J Control Release; 2009 Aug; 137(3):173. PubMed ID: 19520124
    [No Abstract]   [Full Text] [Related]  

  • 2. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression.
    Murua A; Orive G; Hernández RM; Pedraz JL
    J Control Release; 2009 Aug; 137(3):174-8. PubMed ID: 19376171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression.
    Peduto G; Rinsch C; Schneider BL; Rolland E; Aebischer P
    Transplantation; 2000 Jul; 70(1):78-85. PubMed ID: 10919579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolongation of xenograft survival by combining donor-specific intravenous presensitization with FK 506.
    Iwata H; Umeda Y; Matsuno Y; Yoshikawa S; Marui T; Miyauchi T; Takagi H; Mori Y; Hirose H
    Transplant Proc; 2002 Nov; 34(7):2745-8. PubMed ID: 12431592
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatocyte xenotransplantation for Nagase's analbuminemic rats: the effect of FK506.
    Horimoto H; Kokudo N; Otsu I; Nozawa M
    Transplant Proc; 1996 Apr; 28(2):829-30. PubMed ID: 8623421
    [No Abstract]   [Full Text] [Related]  

  • 6. Pretreatment with splenectomy and FK506 in xeno-lung transplantation.
    Takeda M; Kawauchi M; Nakajima J; Furuse A
    Transplant Proc; 1996 Jun; 28(3):1435-6. PubMed ID: 8658728
    [No Abstract]   [Full Text] [Related]  

  • 7. Inducing host acceptance to encapsulated xenogeneic myoblasts.
    Rinsch C; Peduto G; Schneider BL; Aebischer P
    Transplantation; 2001 Feb; 71(3):345-51. PubMed ID: 11233892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early treatment of multiple and spreading lichen striatus with topical tacrolimus.
    Jo JH; Jang HS; Park HJ; Kim MB; Oh CK; Kwon KS
    J Am Acad Dermatol; 2007 Nov; 57(5):904-5. PubMed ID: 17939946
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery.
    Schneider BL; Schwenter F; Pralong WF; Aebischer P
    Mol Ther; 2003 Apr; 7(4):506-14. PubMed ID: 12727114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile.
    Uchida H; Kobayashi E; Ogino Y; Mizuta K; To H; Okabe R; Hashizume K; Fujimura A
    Transplant Proc; 1999 Nov; 31(7):2751-3. PubMed ID: 10578276
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max).
    Ishibashi M; Yoshida K; Ozono S; Hirao Y; Takahashi K; Kawamura Y; Ohara K
    Transplant Proc; 2001; 33(1-2):559-60. PubMed ID: 11266958
    [No Abstract]   [Full Text] [Related]  

  • 12. Tacrolimus is not a preventive agent for occupational skin diseases.
    Jungbauer F; Coenraads PJ
    J Am Acad Dermatol; 2007 Mar; 56(3):519-20; author reply 520. PubMed ID: 17317492
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment.
    Rongioletti F; Zaccaria E; Cozzani E; Parodi A
    J Am Acad Dermatol; 2008 Mar; 58(3):530-2. PubMed ID: 18280368
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical tacrolimus treatment for localized pretibial bullous phemphigoid.
    Calcaterra R; Carducci M; Franco G; Mussi A; Morrone A
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):177-9. PubMed ID: 18410329
    [No Abstract]   [Full Text] [Related]  

  • 15. Recalcitrant acrodermatitis continua of hallopeau treated with calcitriol and tacrolimus 0.1% topical treatment.
    Brunasso AM; Lo Scocco G; Massone C
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(10):1272-3. PubMed ID: 18422537
    [No Abstract]   [Full Text] [Related]  

  • 16. Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream.
    Bilaç DB; Ermertcan AT; Sahin MT; Oztürkcan S
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):72-3. PubMed ID: 18355205
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent dermatitis after solitary envenomation by jellyfish partially responded to tacrolimus ointment 0.1%.
    Rallis E; Limas C
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1287-8. PubMed ID: 17894742
    [No Abstract]   [Full Text] [Related]  

  • 18. Host-derived angiogenesis maintains bone blood flow after withdrawal of immunosuppression.
    Ohno T; Pelzer M; Larsen M; Friedrich PF; Bishop AT
    Microsurgery; 2007; 27(8):657-63. PubMed ID: 17935153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo.
    Sehgal VN
    J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1218-9. PubMed ID: 19192018
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful association in the treatment of pityriasis lichenoides et varioliformis acuta.
    Di Costanzo L; Balato N; La Bella S; Balato A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):971-2. PubMed ID: 19175486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.